Ernexa ERNA-101 preclinical data shows tumor control in ovarian cancer models

New preclinical results for ERNA-101 were selected for a Flash Talk at a Nature Conferences meeting. Data presented Oct. 6, 2026, at MD Anderson's Next-Generation Cancer Therapeutics meeting in Houston, showed ERNA-101 drove immune-cell recruitment, improved tumor control and survival in ovarian cancer models, and demonstrated tumor-site localization.